[email protected]

Dilemmas in the Dosing of Heart Failure Drugs:Titrating

In contrast, small studies have suggested that using doses in the range of 100200 mg spironolactone daily may increase diuretic efficacy in those thought to have diuretic resistance and improve symptoms of congestion. 3638 The Aldosterone Targeted NeuroHormonal Combined with Natriuresis Therapy Heart Failure study evaluated EPHESUS:Eplerenone Post-Acute Myocardial Infarction Heart Aug 23, 2021 · Pitt B, Remme W, Zannad F, et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.

Effect of adding hydrochlorothiazide to usual treatment of

Aug 13, 2021 · Introduction. Acute decompensated heart failure (ADHF) is the leading cause of hospitalization in patients aged 65 years or older 1, accounting for approximately 800,000 admissions in the United States, with a substantial impact on both morbidity and mortality 2.According to estimates, 1 every 2 patients is readmitted within 6 months with in-hospital mortality ranging from 4 to 12% 3. Efficacy and Safety of Spironolactone in Acute Heart FailureJul 12, 2017 · Efficacy and Safety of Spironolactone in Acute Heart Failure JN Learning is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit from articles, audio, Clinical Challenges and more. Efficacy and Safety of Spironolactone in HFpEF and CKD Jan 11, 2019 · In this analysis, the primary safety outcome was drug discontinuation due to an AE of persistent hyperkalemia (>5.5 mmol/L), worsening kidney function (creatinine levels >3.0 mg/dl), anaphylactic reaction or intolerance, or gynecomastia. The primary efficacy outcome was the primary TOPCAT study composite of cardiovascular death, HF hospitalization, or aborted cardiac arrest.

Efficacy and safety of dapagliflozin in acute heart

Nov 02, 2020 · Background:Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces cardiovascular death and worsening heart failure in patients with chronic heart failure and reduced ejection fraction.Early initiation during an acute heart failure (AHF) hospitalization may facilitate decongestion, improve natriuresis, and facilitate safe transition to a beneficial outpatient therapy for Efficacy and safety of spironolactone in acute heart title = "Efficacy and safety of spironolactone in acute heart failure:The ATHENA-HF randomized clinical trial", abstract = "IMPORTANCE:Persistent congestion is associated with worse outcomes in acute heart failure (AHF). Mineralocorticoid receptor antagonists administered at high doses may relieve congestion, overcome diuretic resistance, and mitigate the effects of adverse neurohormonal Efficacy and safety of spironolactone in the heart failure Background:Recent studies have shown the efficacy for using spironolactone to treat heart failure with reduced ejection fraction (HFrEF), but the efficacy of spironolactone for heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) is unclear.

Efficacy and safety of spironolactone in the heart failure

Mar 15, 2019 · Background:Recent studies have shown the efficacy for using spironolactone to treat heart failure with reduced ejection fraction (HFrEF), but the efficacy of spironolactone for heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) is unclear. Relative Efficacy of - Heart Failure ReviewsJul 30, 2019 · This study aims to assess the comparative benefit and risk profile of treatment with mineralocorticoid receptor antagonists (MRAs) with regard to all-cause mortality (primary endpoint), cardiovascular mortality, or heart failure (HF)related hospitalization (secondary endpoints) and the safety endpoints hyperkalemia, acute renal failure, and gynecomastia in patients with chronic HF. Spironolactone In The Treatment of Heart Failure - Full Jan 27, 2021 · The purpose of this study is to determine whether the treatment of patients with HFmrEF and HFpEF at high risk of cardiovascular events with the mineralocorticoid receptor antagonist (MRA) spironolactone reduces a composite of recurrent heart failure hospitalizations and cardiovascular mortality. Condition or disease.

Spironolactone use is associated with improved outcomes in

Jan 17, 2020 · 1 Introduction. Heart failure (HF) with left ventricular ejection fraction (LVEF) of 4049% was first proposed in 2013 American College of Cardiology/American Heart Association guidelines as an intermediate group. 1 In 2016, the European Society of Cardiology HF guidelines defined this distinct group as HF with midrange ejection fraction (HFmrEF) 2 and indicated the need for more research Update on the Impact of Comorbidities on the Efficacy and Apr 09, 2021 · Purpose of Review Multiple newer medications benefit patients with heart failure with reduced ejection fraction (HFrEF). While these therapies benefit the broad population with HFrEF, the efficacy and safety of these therapies have been less well characterized in patients with significant comorbidities. Recent Findings Common comorbidities of high interest in heart failure (HF) include Efficacy and safety of spironolactone for the treatment of Background:This study will investigate the efficacy and safety of spironolactone for the treatment of acute heart failure (AHF). Methods:The following electronic databases will be retrieved in PUBMED, EMBASE, Cochrane Library, Web of Science, CINAHL, CBM, CNKI, and VIP database from inception through present. Two researchers will independently screen and assess the obtained literatures and